EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative cost analysis of Eluvia™ versus Zilver ® PTX ® in treating femoropopliteal peripheral artery disease utilizing real-world data

Elizabeth A Genovese iD, Abimbola O Williams iD, Ryoko Sato iD, Alysha M McGovern iD, Michael R Jaff iD

Journal of Comparative Effectiveness Research · 2026-11 · 15 (11)

DOI: 10.57264/cer-2026-0126 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-11. Verfasst von Elizabeth A Genovese und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular Surgery & Endovascular Therapy, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Popliteal Artery, Drug-Eluting Stents, Femoral Artery. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the hospital-based costs among patients with femoropopliteal artery (FPA) disease treated with Eluvia™ versus Zilver ® PTX ® drug-eluting stents using a large real-world USA hospital database. Materials & methods: This retrospective study included adults in the Premier Healthcare Database who underwent lower extremity FPA endovascular revascularization with Eluvia or Zilver PTX between 1 April 2019 and 31 March 2022. Total hospital-based costs during the index procedure and cumulative 1- and 2-year post-discharge follow-up were compared using multivariable generalized linear models adjusted for age, sex, race and baseline chronic limb-threatening ischemia (CLTI) status. Prespecified subgroup analyses were conducted by care setting (hospital inpatient and hospital outpatient) and among patients with chronic kidney disease (CKD) and CLTI.

Results

A total of 7208 patients were included, comprising 4218 treated with Eluvia and 2990 treated with Zilver PTX. Patients treated with Eluvia had a higher prevalence of several comorbidities, including congestive heart failure and CKD. Unadjusted mean hospital-based index procedure costs were similar between groups (Eluvia, $28,631 vs Zilver PTX, $28,359; difference, -$272; p = 0.7233). After adjustment, mean index procedure hospital-based costs did not differ significantly between treatment groups ($30,031, p = 0.8491). However, Eluvia was associated with lower adjusted cumulative hospital-based costs at the 1-year (difference, $4,017; p = 0.0066) and 2-year (difference, $6250; p = 0.0021) follow-up. Similar associations were observed in the hospital inpatient and CKD subgroups, whereas no statistically significant differences were observed in the CLTI subgroup.

Conclusion

Across patients undergoing femoropopliteal endovascular revascularization, Eluvia was associated with significantly lower post-discharge cumulative hospital-based follow-up costs than Zilver PTX while index procedure costs were comparable. These findings reflect hospital-based costs captured within participating hospitals and do not include medication costs or costs of care received outside the Premier Healthcare Database; therefore, they should not be interpreted as total healthcare costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseasePopliteal ArteryDrug-Eluting StentsFemoral ArteryEndovascular ProceduresHumansRetrospective StudiesFemaleAgedMaleHospital CostsUnited StatesMiddle AgedCosts and Cost AnalysisComparative Effectiveness Research

Stichwörter der Autor:innen

cost analysisdrug-eluting stenteconomic evaluationendovascular revascularizationfemoropopliteal artery interventionshealth economicshealthcare resource utilizationhospital costsperipheral artery diseasereal-world evidence

Autor:innen und Institutionen

  • Division of Vascular Surgery & Endovascular Therapy, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Boston Scientific, Marlborough, MA 01752, USA.
  • Boston Scientific, Maple Grove, MN 55311, USA.

ORCID-Profile: Elizabeth A Genovese, Abimbola O Williams, Ryoko Sato, Alysha M McGovern, Michael R Jaff

Zitieren

APA

Genovese, E. A., Williams, A. O., Sato, R., McGovern, A. M., & Jaff, M. R. (2026). Comparative cost analysis of Eluvia™ versus Zilver ® PTX ® in treating femoropopliteal peripheral artery disease utilizing real-world data. Journal of Comparative Effectiveness Research, 15(11). https://doi.org/10.57264/cer-2026-0126

Vancouver

Genovese EA, Williams AO, Sato R, McGovern AM, Jaff MR. Comparative cost analysis of Eluvia™ versus Zilver ® PTX ® in treating femoropopliteal peripheral artery disease utilizing real-world data. Journal of Comparative Effectiveness Research. 2026;15(11). doi:10.57264/cer-2026-0126

BibTeX
@article{Genovese2026,
  author = {Genovese, Elizabeth A and Williams, Abimbola O and Sato, Ryoko and McGovern, Alysha M and Jaff, Michael R},
  title = {Comparative cost analysis of Eluvia™ versus Zilver ® PTX ® in treating femoropopliteal peripheral artery disease utilizing real-world data},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.57264/cer-2026-0126}
}
Kostenlos starten →